Highlights

  • This EORTC survey found that European BM management is not according to European guidelines.
  • BM screening is not uniform, prognostic classifications are not often used, and MUT + NSCLC patients receive more intensive local treatment.

  • Efforts in harmonisation of management of BM should be pursued by cancer societies.

  • For MUT + NSCLC patients, specific BM guidelines and trials are required.